|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Matrix_Laboratories
Merck KGaA's generics business
Agila Specialties
Abbott Laboratories' non-U.S. developed markets specialty and branded generics business
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:dissolved
|
2020
|
|
gptkbp:foundedBy
|
gptkb:Milan_Puskar
gptkb:Don_Panoz
|
|
gptkbp:foundedYear
|
1961
|
|
gptkbp:headquartersLocation
|
gptkb:Canonsburg,_Pennsylvania,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mylan Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Heather_Bresch
gptkb:Robert_J._Coury
|
|
gptkbp:mergedInto
|
gptkb:Upjohn
|
|
gptkbp:notableEvent
|
EpiPen pricing controversy
|
|
gptkbp:notableProduct
|
gptkb:EpiPen
|
|
gptkbp:numberOfEmployees
|
35000
|
|
gptkbp:parentCompany
|
gptkb:Viatris
|
|
gptkbp:products
|
generic drugs
over-the-counter drugs
branded drugs
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:successor
|
gptkb:Viatris
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_MYL
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.mylan.com/
|
|
gptkbp:bfsParent
|
gptkb:Milan_Puskar
|
|
gptkbp:bfsLayer
|
7
|